- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00447226
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- GSK Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46219
- GSK Investigational Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- GSK Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- GSK Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- GSK Investigational Site
-
-
New York
-
Albany, New York, United States, 12206
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- GSK Investigational Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78731
- GSK Investigational Site
-
Bedford, Texas, United States, 76022
- GSK Investigational Site
-
Dallas, Texas, United States, 75246
- GSK Investigational Site
-
El Paso, Texas, United States, 79915
- GSK Investigational Site
-
Fort Worth, Texas, United States, 76104
- GSK Investigational Site
-
Tyler, Texas, United States, 75702
- GSK Investigational Site
-
Webster, Texas, United States, 77598-4420
- GSK Investigational Site
-
-
Virginia
-
Leesburg, Virginia, United States, 20176
- GSK Investigational Site
-
Newport News, Virginia, United States, 23606
- GSK Investigational Site
-
-
Washington
-
Spokane, Washington, United States, 99202
- GSK Investigational Site
-
Vancouver, Washington, United States, 98684
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent.
- Age >= 18 years old.
- Life expectancy of at least 12 weeks.
- Have histologically confirmed ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancer.
- Have ErbB2-positive cancer as determined by Fluorescence In Situ Hybridization (FISH) assay.
- Have documented tumor progression after receiving all standard/approved chemotherapies per National Comprehensive Cancer Network (NCCN) guidelines (V1) for their specific cancer and no approved therapy exists.
- Have one or more tumors measurable by medical imaging and assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Have archived tumor tissue available for biomarker analysis.
- Have a negative serum pregnancy test if female of childbearing potential.
- Any chemotherapy, major surgery, or irradiation must have been completed at least 3 weeks prior to receiving study drug (6 weeks for mitomycin-C or nitrosourea) and subject must have recovered from all toxicities incurred as a result of previous therapy.
- Have a gastrointestinal tract intact enough to swallow and assure absorption of the drug.
- Women of childbearing potential must have a negative serum pregnancy test at screening and must use an approved contraceptive method, if appropriate (for example, intrauterine device, birth control pills, or barrier device) beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product. Males able to father a child must practice adequate methods of birth control or practice complete abstinence from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment.
- Have a cardiac ejection fraction within institutional range of normal as measured by either echocardiogram or multigated acquisition scans. The same method of cardiac evaluation must be used consistently throughout the study.
- Subjects must have adequate organ function:
Hematologic:
absolute neutrophil count >1.5 x 109/L hemoglobin >9 g/dL platelets >75 x 109/L
Hepatic:
albumin >2.5 g/dL serum bilirubin <1.25 x upper limit of normal aspartate aminotransferase/alanine aminotransferase <3 x ULN if no documented liver metastases aspartate aminotransferase/alanine aminotransferase <5 x ULN with documented liver metastases
Renal:
serum creatinine <2.0 mg/dL
- OR - calculated creatinine clearance1 >40 mL/min
Exclusion Criteria:
- Have New York Heart Association Class III or IV, cardiac disease, myocardial infarction within past 6 months, unstable arrhythmia or evidence of ischemia on electrocardiogram.
- Subjects who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study or who have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.
- Concurrent treatment with an investigational agent or participation in another treatment clinical trial.
- Prior lapatinib therapy.
- ECOG Performance Status 2 or greater.
- Subjects receiving concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy (including an ErbB1 and/or ErbB2 inhibitor), or hormonal therapy for treatment of their cancer. Concurrent treatment with bisphosphonates is allowed.
- History of allergic reactions attributed to compounds of similar chemical composition (quinazolines) to lapatinib.
- Concurrent treatment with prohibited medications.
- Malabsorption syndrome, resection of the small bowel or active, uncontrolled ulcerative colitis.
- Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety.
- Uncontrolled infection.
- Pregnant or lactating females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lapatinib Oral Tablets
|
Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks.
After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression.
Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo.
Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression.
Those who progress on lapatinib will be withdrawn from the study.
|
Placebo Comparator: Placebo Control
|
Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks.
After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression.
Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo.
Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression.
Those who progress on lapatinib will be withdrawn from the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With the Indicated Tumor Response at 12 Weeks From First Dose
Time Frame: Week 12
|
Per Response Evaluation Criteria In Solid Tumors (RECIST): Complete response (CR), disappearance of all lesions; partial response (PR), >=30% decrease in the measurements of the largest lesions; stable disease (SD), insufficient shrinkage to qualify for PR or insufficient increase to qualify for progressive disease (PD); PD, >=20% increase in measurements of lesions or appearance of new lesions.
Data were not fully analyzed due to early study termination.
|
Week 12
|
Percentage of Participants Who Remained Progression-free 12 Weeks After Randomization
Time Frame: Week 12 after randomization.
|
The percentage of participants who did not show signs of progressive disease 12 weeks after receiving lapatinib or placebo in Stage 2 of the study (participants who maintained SD in Stage 1 were randomized to either lapatinib or placebo) was measured.
Formal statistics for treatment comparison were not performed, due to early study termination.
The percentage of participants displayed below includes those with CR + PR + SD.
|
Week 12 after randomization.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response
Time Frame: (assessments every 12 weeks until death for withdrawn participants and every 3 weeks for participants continuing on lapatinib)
|
Duration of response was calculated as the time from first documented partial response (PR; >=30% decrease in the measurements of the largest lesions) or complete response (CR; disappearance of all lesions) until disease progression, the time when the participant began a new anti-cancer therapy, or death.
Data were not analyzed due to early study termination.
|
(assessments every 12 weeks until death for withdrawn participants and every 3 weeks for participants continuing on lapatinib)
|
Progression-free Survival (PFS)
Time Frame: From start of treatment to disease progression/death (assessments every 12 weeks until death for withdrawn participants and every 3 weeks for participants continuing on lapatinib)
|
Progression-free survival was calculated as the time from the start of treatment until disease progression or death.
For participants who did not have disease progression or did not die, the date on which alternative anti-cancer therapy began was used, or the date of last contact (if sooner).
The word used for such participants was "censored".
Data were not analyzed due to early study termination.
|
From start of treatment to disease progression/death (assessments every 12 weeks until death for withdrawn participants and every 3 weeks for participants continuing on lapatinib)
|
Time to Disease Progression (TTP)
Time Frame: From start of treatment to disease progression/death (up to 83.3 weeks)
|
Time to disease progression was calculated as the time from the start of treatment to disease progression or death due to disease progression.
For participants who did not progress, the date of last contact was used and for those who died due to other causes, the date of death was used.
The word used for such participants was "censored".
As the median value in the placebo arm was not reached (2 participants were censored and 2 were ongoing), results for the placebo arm are not displayed in the table below.
|
From start of treatment to disease progression/death (up to 83.3 weeks)
|
Number of Participants With the Indicated Change in Cancer Antigen-125 (CA-125) Levels From Day 1
Time Frame: Pre-dose and every 6 weeks until withdrawal (up to 84.1 weeks)
|
CA-125 is a "tumor marker", found in greater concentration in tumor cells than other cells of the body.
In particular, CA-125 is present in greater concentration in ovarian cancer cells than in other cells.
A decreasing level generally indicates that therapy has been effective, whereas an increasing level indicates tumor recurrence.
|
Pre-dose and every 6 weeks until withdrawal (up to 84.1 weeks)
|
Incidence of MET Amplification in Gastric Cancer
Time Frame: Performed on archived tissue collected at screening.
|
The number of gastric cancer participants with MET amplification (determined by fluorescence in situ hybridization [FISH] assay) compared to the total number of gastric cancer participants screened was to be recorded.
Amplification of the MET gene has been reported to be related to carcinogenesis, progression of gastric cancer, and poor prognosis.
Data were not analyzed due to early study termination.
|
Performed on archived tissue collected at screening.
|
Incidence of ErbB2-positive Participants
Time Frame: Screening
|
The number of ErbB2-positive participants (determined by FISH assay) compared to the total number of participants screened was to be recorded.
Over-expression of ErbB2 has been correlated with an overall poor prognosis.
Data were not analyzed, due to early study termination.
|
Screening
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LPT108741
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Oral lapatinib tablets or placebo tablets
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Not yet recruiting
-
Suzhou Kintor Pharmaceutical Inc,Terminated
-
Neurogen CorporationTerminatedEarly Parkinson DiseaseUnited States
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Non-Insulin-Dependent Diabetes MellitusGermany, United States
-
Neurogen CorporationTerminatedRestless Legs SyndromeUnited States
-
Harmony Biosciences, LLCActive, not recruitingPrader-Willi SyndromeUnited States
-
GlaxoSmithKlineCompletedAdenocarcinomaNetherlands, United States, Peru
-
GlaxoSmithKlineCompletedPurpura, Thrombocytopenic, Idiopathic | Idiopathic Thrombocytopenic PurpuraJapan
-
GlaxoSmithKlineCompletedSquamous Cell Carcinoma of Head and NeckSpain, France, Peru, India, Greece
-
Paratek Pharmaceuticals IncActive, not recruitingMycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary InfectionUnited States